Status:
COMPLETED
Gut and Azithromycin Mechanisms in Infants and Children II
Lead Sponsor:
University of California, San Francisco
Collaborating Sponsors:
Centre de Recherche en Sante de Nouna, Burkina Faso
Conditions:
Malaria
Eligibility:
All Genders
8-59 years
Phase:
PHASE4
Brief Summary
Childhood mortality is decreasing worldwide. However, many sub-Saharan countries still have high children under 5 mortality rates. The MORDOR trial in Niger, Tanzania, and Malawi demonstrated a near 1...
Detailed Description
The investigators' previous MORDOR I research demonstrated a significant reduction in all-cause child mortality after biannual mass azithromycin distribution. In three sub-Saharan Africa countries, (i...
Eligibility Criteria
Inclusion
- Between 8 days and 59 months old
- Primary residence within catchment area of study site
- Available for full 6 month study
- No known allergy to macrolides/azalides
- Appropriate written informed consent from at least one parent or guardian
- Able to feed orally
Exclusion
- \<8 days old or \>59 months
- Primary residence outside catchment area of study site
- Not available for full 6 month study
- Known allergy to macrolides/azalides
- No written informed consent from at least one parent or guardian
- Unable to feed orally
Key Trial Info
Start Date :
August 21 2020
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
June 1 2022
Estimated Enrollment :
449 Patients enrolled
Trial Details
Trial ID
NCT04315272
Start Date
August 21 2020
End Date
June 1 2022
Last Update
June 29 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Centre de Recherche en santé de nouna
Nouna, Boucle du Mouhoun, Burkina Faso